Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Recruiting · NCT07095868 · Registry updated 2026-08-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Selected Types of Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT07095868 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Everest Medicines (Beijing) Co., Ltd. | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Changsha | China | 6 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 16 |
| Nanjing Drum Tower Hospital | Nanjing | China | 22 |
| NEXT Oncology | Fairfax | United States | 31 |
| Shanghai Pulmonary Hospital | Shanghai | China | 72 |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | China | 32 |